Patents by Inventor Fernando Camacho

Fernando Camacho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase I?
    Patent number: 7626027
    Abstract: The present invention discloses and claims compounds of formula (I) wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase I?, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: December 1, 2009
    Assignee: Aventis Pharmaceuticals Inc
    Inventors: William A. Metz, Jr., Frank Halley, Gilles Dutruc-Rosset, Yong Mi Choi-Sledeski, Gregory Bernard Poli, David Marc Fink, Gilles Doerflinger, Bao-Guo Huang, Ann Marie Gelormini, Juan Anotonio Gamboa, Andrew Giovanni, Joachim E. Roehr, Joseph T. Tsay, Fernando Camacho, William Joseph Hurst, Stephen Wayne Harnish, Yulin Chiang
  • SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie
    Publication number: 20080200496
    Abstract: The present invention discloses and claims compounds of formula (I) wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase I?, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
    Type: Application
    Filed: April 21, 2008
    Publication date: August 21, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William A. METZ, Frank HALLEY, Gilles DUTRUC-ROSSET, Yong Mi CHOI-SLEDESKI, Gregory Bernard POLI, David Marc FINK, Gilles DOERFLINGER, Bao-Guo HUANG, Ann Marie GELORMINI, Juan Antonio GAMBOA, Andrew GIOVANNI, Joachim E. ROEHR, Joseph T. TSAY, Fernando CAMACHO, William Joseph HURST, Stephen Wayne HARNISH, Yulin CHIANG
  • Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
    Patent number: 7402672
    Abstract: The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: July 22, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William A. Metz, Jr., Frank Halley, Gilles Dutruc-Rosset, Yong Mi Choi-Sledeski, Gregory Bernard Poli, David Marc Fink, Gilles Doerflinger, Bao-Guo Huang, Ann Marie Gelormini, Juan Antonio Gamboa, Andrew Giovanni, Joachim E. Roehr, Joseph T. Tsay, Fernando Camacho, William Joseph Hurst, Stephen Wayne Harnish, Yulin Chiang
  • Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
    Publication number: 20050131012
    Abstract: The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 16, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: William Metz, Frank Halley, Gilles Dutruc-Rosset, Yong Choi-Sledeski, Gregory Bernard Poli, David Fink, Gilles Doerflinger, Bao-Guo Huang, Ann Gelormini, Juan Gamboa, Andrew Giovanni, Joachim Roehr, Joseph Tsay, Fernando Camacho, William Hurst, Stephen Harnish, Yulin Chiang
  • Osteopontin, oligodendrocytes and myelination
    Publication number: 20040033226
    Abstract: Osteopontin is a marker for oligodendrocyte precursor cells. Osteopontin also modulates oligodendrocyte differentiation and central nervous system myelination. Osteopontin induces migration of oligodendrocyte precursors.
    Type: Application
    Filed: June 24, 2003
    Publication date: February 19, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Jean Merrill, Su-Fen Pu, Olga Khorkova, Zhongqi Ji, Fernando Camacho, Steve Busch, Min Wang, Ting Chen, Robert Dinerstein, Zhengbin Yao, Yangde Chen, Xin Zhang, Karen Chandross, Lan Lee
  • Screening methods for altering circadian rhythms and for human casein kinase I &dgr; and/or &egr; phosphorylation of human clock proteins, period 1, -2 and -3
    Patent number: 6555328
    Abstract: The present invention is directed to methods to identify test compounds that alter circadian rhythms of mammals, and more specifically, directed to methods for determining the ability of a test compound to alter hCKI &dgr; and &egr; phosphorylation of a human Period protein. The present invention is also directed to a method for determing the ability of a test compound to selectively alter phosphorylation, interaction with, or alternatively degradation, of one or more human Period proteins relative to its ability to alter phosphorylation, interaction with, or alternatively degradation, of a different human Period protein.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: April 29, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: George A. Keesler, Cesare Mondadori, Zhengbin Yao, Fernando Camacho